#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Promiscuous RNA Binding Ensures Effective Encapsidation of APOBEC3 Proteins by HIV-1


APOBEC3 proteins are cell-encoded restriction factors that counteract infections, particularly by retroviruses such as HIV-1, and retrotransposons. When packaged into HIV-1 particles, APOBEC3G and APOBEC3F both inhibit reverse transcription and induce destructive hypermutation in viral DNA. The mechanism of APOBEC3 virion packaging awaits elucidation, though a dependency on RNA binding has been established. Here, we employed a cross-linking and next generation sequencing approach to determine which RNAs are bound to A3G and A3F in HIV-1 infected cells. We show that both proteins bind to multiple different RNAs, including viral RNA as well as cellular coding and non-coding RNAs, with relatively little evidence of selectivity. We then developed a complementation assay to address the diversity of RNAs that can act as substrates for A3G/F virion packaging. Consistent with the RNA binding profiles, many RNAs can promote packaging provided that those RNAs are, themselves, packaged. These observations suggest that APOBEC3 packaging lacks selectivity and is driven simply by the non-specific RNA binding capabilities of these proteins. We speculate that this model accounts for the broad range of retro-elements that are susceptible to repression by individual APOBEC3 proteins, and also that such substrates cannot escape APOBEC3-mediated inhibition through sequence variation.


Vyšlo v časopise: Promiscuous RNA Binding Ensures Effective Encapsidation of APOBEC3 Proteins by HIV-1. PLoS Pathog 11(1): e32767. doi:10.1371/journal.ppat.1004609
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004609

Souhrn

APOBEC3 proteins are cell-encoded restriction factors that counteract infections, particularly by retroviruses such as HIV-1, and retrotransposons. When packaged into HIV-1 particles, APOBEC3G and APOBEC3F both inhibit reverse transcription and induce destructive hypermutation in viral DNA. The mechanism of APOBEC3 virion packaging awaits elucidation, though a dependency on RNA binding has been established. Here, we employed a cross-linking and next generation sequencing approach to determine which RNAs are bound to A3G and A3F in HIV-1 infected cells. We show that both proteins bind to multiple different RNAs, including viral RNA as well as cellular coding and non-coding RNAs, with relatively little evidence of selectivity. We then developed a complementation assay to address the diversity of RNAs that can act as substrates for A3G/F virion packaging. Consistent with the RNA binding profiles, many RNAs can promote packaging provided that those RNAs are, themselves, packaged. These observations suggest that APOBEC3 packaging lacks selectivity and is driven simply by the non-specific RNA binding capabilities of these proteins. We speculate that this model accounts for the broad range of retro-elements that are susceptible to repression by individual APOBEC3 proteins, and also that such substrates cannot escape APOBEC3-mediated inhibition through sequence variation.


Zdroje

1. Holmes RK, Malim MH, Bishop KN (2007) APOBEC-mediated viral restriction: not simply editing? Trends Biochem Sci 32: 118–128. 17303427

2. Desimmie B a, Delviks-Frankenberrry K a, Burdick RC, Qi D, Izumi T, et al. (2013) Multiple APOBEC3 Restriction Factors for HIV-1 and One Vif to Rule Them All. J Mol Biol: 1–26.

3. LaRue RS, Andrésdóttir V, Blanchard Y, Conticello SG, Derse D, et al. (2009) Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol 83: 494–497. doi: 10.1128/JVI.01976-08 18987154

4. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 4–8. 12167863

5. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99–103. 12808466

6. Gaddis NC, Sheehy AM, Ahmad KM, Swanson M, Bishop KN, et al. (2004) Further Investigation of Simian Immunodeficiency Virus Vif Function in Human Cells. J Virol 78: 12041–12046. 15479843

7. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-mahrt SK, et al. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803–809. 12809610

8. Okeoma CM, Lovsin N, Peterlin BM, Ross SR (2007) APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445: 927–930. 17259974

9. Turelli P, Mangeat B, Jost S, Vianin S, Trono D (2004) Inhibition of hepatitis B virus replication by APOBEC3G. Science 303: 1829.

10. Narvaiza I, Linfesty DC, Greener BN, Hakata Y, Pintel DJ, et al. (2009) Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog 5: e1000439. doi: 10.1371/journal.ppat.1000439 19461882

11. Esnault C, Heidmann O, Delebecque F, Dewannieux M, Ribet D, et al. (2005) APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433: 430–433. 15674295

12. Marin M, Rose KM, Kozak SL, Kabat D (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9: 1398–1403. 14528301

13. Yu X, Yu Y, Liu B, Luo K, Kong W, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302: 1056–1060. 14564014

14. Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9: 1404–1407. 14528300

15. Guo Y, Dong L, Qiu X, Wang Y, Zhang B, et al. (2014) Structural basis for hijacking CBF-β and CUL5 E3 ligase complex by HIV-1 Vif. Nature 505: 229–233. doi: 10.1038/nature12884 24402281

16. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94–98. 12808465

17. Bishop KN, Verma M, Kim E-Y, Wolinsky SM, Malim MH (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4: e1000231. 19057663

18. Iwatani Y, Chan DSB, Wang F, Maynard KS, Sugiura W, et al. (2007) Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res 35: 7096–7108. 17942420

19. Gillick K, Pollpeter D, Phalora P, Kim E-Y, Wolinsky SM, et al. (2013) Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. J Virol 87: 1508–1517. doi: 10.1128/JVI.02587-12 23152537

20. Navarro F, Bollman B, Chen H, König R, Yu Q, et al. (2005) Complementary function of the two catalytic domains of APOBEC3G. Virology 333: 374–386. 15721369

21. Iwatani Y, Takeuchi H, Strebel K, Levin JG (2006) Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol 80: 5992–6002. 16731938

22. Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH (2009) RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog 5: e1000330. 19266078

23. Chiu Y-L, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, et al. (2005) Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435: 108–114. 15829920

24. Kozak SL, Marin M, Rose KM, Bystrom C, Kabat D (2006) The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J Biol Chem 281: 29105–29119. 16887808

25. Wichroski MJ, Robb GB, Rana TM (2006) Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog 2: e41. 16699599

26. Gallois-Montbrun S, Kramer B, Swanson CM, Byers H, Lynham S, et al. (2007) Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol 81: 2165–2178. 17166910

27. Phalora PK, Sherer NM, Wolinsky SM, Swanson CM, Malim MH (2012) HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies. J Virol 86: 11712–11724. 22915799

28. Izumi T, Burdick R, Shigemi M, Plisov S, Hu W-S, et al. (2013) Mov10 and APOBEC3G localization to processing bodies is not required for virion incorporation and antiviral activity. J Virol 87: 11047–11062. doi: 10.1128/JVI.02070-13 23926332

29. Soros VB, Yonemoto W, Greene WC (2007) Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog 3: e15. 17291161

30. Luo K, Liu B, Xiao Z, Yu Y, Gorelick R, et al. (2004) Amino-Terminal Region of the Human Immunodeficiency Virus Type 1 Nucleocapsid Is Required for Human APOBEC3G Packaging. J Virol 78: 11841–11852. 15479826

31. Schäfer A, Bogerd HP, Cullen BR (2004) Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328: 163–168. 15464836

32. Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, et al. (2004) Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem 279: 35822–35828. 15210704

33. Zennou V, Perez-caballero D, Bieniasz PD (2004) APOBEC3G Incorporation into Human Immunodeficiency Virus Type 1 Particles. J Virol 78: 12058–12061. 15479846

34. Khan MA, Kao S, Miyagi E, Goila-gaur R, Opi S, et al. (2005) Viral RNA Is Required for the Association of APOBEC3G with Human Immunodeficiency Virus Type 1 Nucleoprotein Complexes. J Virol 79: 5870–5874. 15827203

35. Wang T, Tian C, Zhang W, Luo K, Sarkis PTN, et al. (2007) 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J Virol 81: 13112–13124. 17881443

36. Chiu Y, Witkowska HE, Hall SC, Santiago M, Soros VB, et al. (2006) High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci USA 103: 15588–15593. 17030807

37. Berkowitz R, Fisher J, Goff SP (1996) RNA Packaging. In: Kräusslich H-G, editor. Morphogenesis and Maturation of Retroviruses SE - 6. Springer Berlin Heidelberg, Vol. 214. pp. 177–218.

38. Ule J, Jensen KB, Ruggiu M, Mele A, Ule A, et al. (2003) CLIP identifies Nova-regulated RNA networks in the brain. Science 302: 1212–1215. 14615540

39. König J, Zarnack K, Rot G, Curk T, Kayikci M, et al. (2010) iCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution. Nat Struct Mol Biol 17: 909–915.

40. Chi SW, Zang JB, Mele A, Darnell RB (2009) Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 460: 479–486. doi: 10.1038/nature08170 19536157

41. Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 10: R25. doi: 10.1186/gb-2009-10-3-r25 19261174

42. Smit Afa Green (n.d.) Repeat Masker. Available: http://repeatmasker.org.

43. Zufferey R, Nagy D, Mandel R, Naldini L, Trono D (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15: 871–875. 9306402

44. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, et al. (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13: 803–813. 11975847

45. Accola MA, Strack B, Göttlinger HG (2000) Efficient Particle Production by Minimal Gag Constructs Which Retain the Carboxy-Terminal Domain of Human Immunodeficiency Virus Type 1 Capsid-p2 and a Late Assembly Domain. J Virol 74: 5395–5402. 10823843

46. Luban J, Goff SP (1994) Mutational Analysis of cis-Acting Packaging Signals in Human Immunodeficiency Virus Type 1 RNA. J Virol 68: 3784–3793. 8189516

47. Onafuwa-Nuga A a, Telesnitsky A, King SR (2006) 7SL RNA, but not the 54-kd signal recognition particle protein, is an abundant component of both infectious HIV-1 and minimal virus-like particles. RNA 12: 542–546. 16489186

48. Khan M a, Goila-Gaur R, Opi S, Miyagi E, Takeuchi H, et al. (2007) Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology 4: 48. 17631688

49. Onafuwa-nuga AA, King SR, Telesnitsky A (2005) Nonrandom Packaging of Host RNAs in Moloney Murine Leukemia Virus. J Virol 79: 13528–13537. 16227273

50. Gallois-Montbrun S, Holmes RK, Swanson CM, Fernández-Ocaña M, Byers HL, et al. (2008) Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins. J Virol 82: 5636–5642. doi: 10.1128/JVI.00287-08 18367521

51. Bach D, Peddi S, Mangeat B, Lakkaraju A, Strub K, et al. (2008) Characterization of APOBEC3G binding to 7SL RNA. Retrovirology 5: 54. doi: 10.1186/1742-4690-5-54 18597676

52. Sherer NM, Lehmann MJ, Jimenez-Soto LF, Ingmundson A, Horner SM, et al. (2003) Visualization of retroviral replication in living cells reveals budding into multivesicular bodies. Traffic 4: 785–801. 14617360

53. Müller B, Daecke J, Fackler OT, Dittmar T, Zentgraf H, et al. (2004) Construction and Characterization of a Fluorescently Labeled Infectious Human Immunodeficiency Virus Type 1 Derivative. J Virol 78: 10803–10813.

54. Lerner MR, Boyle JA, Hardin JA, Steitz JA, Science S, et al. (1981) Two Novel Classes of Small Ribonucleoproteins Detected by Antibodies Associated with Lupus Erythematosus. Science (80) 211: 400–402. 6164096

55. Hendrick JP, Wolin SL, Rinke J, Steitz JA (1981) Ro small cytoplasmic ribonucleoproteins are a subclass of La ribonucleoproteins : further characterization of the Ro and La Small ribonucleoproteins from uninfected mammalian cells. Mol Cell Biol 12: 1138–1149. 6180298

56. Garcia EL, Onafuwa-Nuga A, Sim S, King SR, Wolin SL, et al. (2009) Packaging of host mY RNAs by murine leukemia virus may occur early in Y RNA biogenesis. J Virol 83: 12526–12534. doi: 10.1128/JVI.01219-09 19776129

57. Swanson MS, Dreyfuss G (1988) heterogeneous nuclear ribonucleoprotein Classification and Purification of Proteins of Heterogeneous Nuclear Ribonucleoprotein Particles by RNA-Binding Specificities. Mol Cell Biol 8: 2237–2241.

58. Makeyev A V, Liebhaber SA (2002) The poly ( C ) -binding proteins: a multiplicity of functions and a search for mechanisms. RNA 8: 265–278. 12003487

59. Pandit S, Zhou Y, Shiue L, Coutinho-Mansfield G, Li H, et al. (2013) Genome-wide analysis reveals SR protein cooperation and competition in regulated splicing. Mol Cell 50: 223–235. doi: 10.1016/j.molcel.2013.03.001 23562324

60. Saunders LR, Barber GN (2003) The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J 17: 961–983. 12773480

61. De Lucas S, Oliveros JC, Chagoyen M, Ortín J (2014) Functional signature for the recognition of specific target mRNAs by human Staufen1 protein. Nucleic Acids Res 42: 4516–4526. doi: 10.1093/nar/gku073 24470147

62. Wilson a C Peterson MG, Herr W (1995) The HCF repeat is an unusual proteolytic cleavage signal. Genes Dev 9: 2445–2458. 7590226

63. Simon JH, Southerling TE, Peterson JC, Meyer BE, Malim MH (1995) Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol 69: 4166–4172. 7769676

64. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, et al. (1985) Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313: 277–284. 2578615

65. Swanson CM, Puffer B a, Ahmad KM, Doms RW, Malim MH (2004) Retroviral mRNA nuclear export elements regulate protein function and virion assembly. EMBO J 23: 2632–2640. 15201866

66. Newman ENC, Holmes RK, Craig HM, Klein KC, Lingappa JR, et al. (2005) Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 15: 166–170. 15668174

67. Holmes RK, Koning FA, Bishop KN, Malim MH (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation: Comparisons with APOBEC3G. J Biol Chem 282: 2587–2595. 17121840

68. Shlyakhtenko LS, Lushnikov AY, Li M, Lackey L, Harris RS, et al. (2011) Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. J Biol Chem 286: 3387–3395. doi: 10.1074/jbc.M110.195685 21123176

69. Gaddis NC, Chertova E, Sheehy AM, Henderson LE, Malim MH (2003) Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J Virol 77: 5810–5820. 12719574

Štítky
Hygiena a epidemiológia Infekčné lekárstvo Laboratórium

Článok vyšiel v časopise

PLOS Pathogens


2015 Číslo 1
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Aktuální možnosti diagnostiky a léčby litiáz
nový kurz
Autori: MUDr. Tomáš Ürge, PhD.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#